CoChat
Sign Up
Cited by 10Adipokines, Inflammation, and Metabolic DiseasesInflammatory Biomarkers in Disease PrognosisNutrition and Health in Aging

Association of plasma cystatin C with all-cause and cause-specific mortality among middle-aged and elderly individuals: a prospective community-based cohort study

Open access
Wu, Jinhua, Liang, Yuemei, Chen, Rong, Xu, Linli, Ou, Zejin, Liang, Haiying, Zhao, Lina·2022·Scientific Reports
DOI 10.1038/s41598-022-24722-4PMC PMC9789032
Open this paper in CoChat — free accountOpen PDF

Abstract

We investigated the associations of plasma cystatin C with all-cause and cause-specific mortality risk and identified potential modifying factors affecting these associations in middle-aged and elderly people (≥ 50 years). This community-based prospective cohort study included 13,913 individuals aged ≥ 50 years from the Health and Retirement Study. Cox proportional hazard models were used to estimate the associations between cystatin C concentrations and the risk of all-cause and cardiovascular and cancer mortality after adjustment for sociodemographic characteristics, lifestyle factors, self-reported medical history, and other potential confounding factors. During a total of 71,988 person-years of follow-up (median: 5.8 years; interquartile range 3.3–7.6 years), 1893 all-cause deaths were documented, including 714 cardiovascular-related and 406 cancer-related deaths. The comparisons of the groups with the highest (quartile 4) and lowest (quartile 1) cystatin C concentrations revealed that the adjusted hazard ratios and 95% confidence intervals were 1.92 (1.62–2.28) for all-cause mortality, 1.98 (1.48–2.65) for cardiovascular mortality, and 1.62 (1.13–2.32) for cancer mortality. The associations of cystatin C concentrations with all-cause, cardiovascular and cancer mortality did not differ substantially when participants were stratified by sex, age, BMI, current smoking status, current alcohol consumption, and regular exercise (all P for interactions > 0.05). Our study indicates that an elevated plasma cystatin C concentration is associated with an increased risk of all-cause, cardiovascular and cancer mortality both men and women among the middle-aged and elderly individuals.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-022-24722-4

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 36

  1. [1]Webster AC Nagler EV Morton RL Masson P Chronic kidney disease Lancet 2017 389 10075 1238 1252 10.1016/S0140-6736(16)32064-5 27887750 · DOI · Paper page
  2. [2]Fried LF Shlipak MG Crump C Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals J. Am. Coll. Cardiol. 2003 41 8 1364 1372 10.1016/S0735-1097(03)00163-3 12706933 · DOI
  3. [3]Tonelli M Wiebe N Culleton B Chronic kidney disease and mortality risk: a systematic review J. Am. Soc. Nephrol. 2006 17 7 2034 2047 10.1681/ASN.2005101085 16738019 · DOI
  4. [4]Ishida K Ishida H Narita M Factors affecting renal function in 119 985 adults over three years QJM 2001 94 10 541 550 10.1093/qjmed/94.10.541 11588213 · DOI
  5. [5]Neugarten J Gender and the progression of renal disease J. Am. Soc. Nephrol. 2002 13 11 2807 2809 10.1097/01.ASN.0000035846.89753.D4 12397053 · DOI
  6. [6]Inker LA Schmid CH Tighiouart H Estimating glomerular filtration rate from serum creatinine and cystatin C N. Engl. J. Med. 2012 367 1 20 29 10.1056/NEJMoa1114248 22762315 PMC4398023 · DOI · Paper page
  7. [7]Mussap M Plebani M Biochemistry and clinical role of human cystatin C Crit. Rev. Clin. Lab. Sci. 2004 41 5–6 467 550 10.1080/10408360490504934 15603510 · DOI
  8. [8]Shlipak MG Sarnak MJ Katz R Cystatin C and the risk of death and cardiovascular events among elderly persons N. Engl. J. Med. 2005 352 20 2049 2060 10.1056/NEJMoa043161 15901858 · DOI
  9. [9]Wasen E Isoaho R Mattila K Vahlberg T Kivelä SL Irjala K Estimation of glomerular filtration rate in the elderly: a comparison of creatinine-based formulae with serum cystatin C J. Intern. Med. 2004 256 1 70 78 10.1111/j.1365-2796.2004.01340.x 15189368 · DOI
  10. [10]Luo J Wang L-P Hu H-F Cystatin C and cardiovascular or all-cause mortality risk in the general population: a meta-analysis Clin. Chim. Acta 2015 450 39 45 10.1016/j.cca.2015.07.016 26192218 · DOI
  11. [11]Fried LF Katz R Sarnak MJ Kidney function as a predictor of noncardiovascular mortality J. Am. Soc. Nephrol. 2005 16 12 3728 3735 10.1681/ASN.2005040384 16251239 · DOI
  12. [12]Einwoegerer CF Domingueti CP Association between increased levels of cystatin C and the development of cardiovascular events or mortality: A systematic review and meta-analysis Arq. Bras. Cardiol. 2018 111 796 807 30281693 PMC6263454
  13. [13]Toft I Solbu M Kronborg J Cystatin C as risk factor for cardiovascular events and all-cause mortality in the general population. The Tromsø Study Nephrol. Dial. Transplant. 2012 27 7 2780 2787 10.1093/ndt/gfr751 22207328 · DOI
  14. [14]Wong G Hayen A Chapman JR Association of CKD and cancer risk in older people J. Am. Soc. Nephrol. 2009 20 6 1341 1350 10.1681/ASN.2008090998 19406977 PMC2689896 · DOI
  15. [15]Weng P-H Hung K-Y Huang H-L Chen J-H Sung P-K Huang K-C Cancer-specific mortality in chronic kidney disease: longitudinal follow-up of a large cohort Clin. J. Am. Soc. Nephrol. 2011 6 5 1121 1128 10.2215/CJN.09011010 21511834 PMC3087779 · DOI
  16. [16]Iff S Craig JC Turner R Reduced estimated GFR and cancer mortality Am. J. Kidney Dis. 2014 63 1 23 30 10.1053/j.ajkd.2013.07.008 23993153 · DOI
  17. [17]Leto G Crescimanno M Flandina C On the role of cystatin C in cancer progression Life Sci. 2018 202 152 160 10.1016/j.lfs.2018.04.013 29654808 · DOI · Paper page
  18. [18]Lees JS Ho F Parra-Soto S Kidney function and cancer risk: An analysis using creatinine and cystatin C in a cohort study EClinicalMedicine 2021 38 101030 10.1016/j.eclinm.2021.101030 34505030 PMC8413238 · DOI
  19. [19]Emberson J Haynes R Dasgupta T Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men J. Int. Med. 2010 268 2 145 154 10.1111/j.1365-2796.2010.02214.x 20337853 · DOI
  20. [20]Hart A Blackwell TL Paudel ML Cystatin C and the risk of frailty and mortality in older men J. Gerontol. Ser. A 2017 72 7 965 970 PMC5458398 28329858
  21. [22]Sonnega A Faul JD Ofstedal MB Langa KM Phillips JW Weir DR Cohort profile: the health and retirement study (HRS) Int. J. Epidemiol. 2014 43 2 576 585 10.1093/ije/dyu067 24671021 PMC3997380 · DOI · Paper page
  22. [24]Li Z-H Zhong W-F Lv Y-B Associations of plasma high-sensitivity C-reactive protein concentrations with all-cause and cause-specific mortality among middle-aged and elderly individuals Immunity Ageing 2019 16 1 1 8 10.1186/s12979-019-0168-5 31708993 PMC6833146 · DOI
  23. [25]Shen Y Zhang Y Xiong S Zhu X Ke C High-sensitivity C-reactive protein and cystatin C independently and jointly predict all-cause mortality among the middle-aged and elderly Chinese population Clin. Biochem. 2019 65 7 14 10.1016/j.clinbiochem.2018.12.012 30592989 · DOI
  24. [26]Little RJ Rubin DB Statistical Analysis with Missing Data 2019 New York Wiley
  25. [27]Grambsch PM Therneau TM Proportional hazards tests and diagnostics based on weighted residuals Biometrika 1994 81 3 515 526 10.1093/biomet/81.3.515 · DOI · Paper page
  26. [28]Barr EL Reutens A Magliano DJ Cystatin C estimated glomerular filtration rate and all-cause and cardiovascular disease mortality risk in the general population: AusDiab study Nephrology 2017 22 3 243 250 10.1111/nep.12759 26938304 · DOI
  27. [29]Okura T Jotoku M Irita J Association between cystatin C and inflammation in patients with essential hypertension Clin. Exp. Nephrol. 2010 14 6 584 588 10.1007/s10157-010-0334-8 20809110 · DOI
  28. [30]Donahue RP Stranges S Rejman K Rafalson LB Dmochowski J Trevisan M Elevated cystatin C concentration and progression to pre-diabetes: The Western New York study Diabetes Care 2007 30 7 1724 1729 10.2337/dc07-0040 17456840 · DOI
  29. [31]Kestenbaum B Rudser KD De Boer IH Differences in kidney function and incident hypertension: The multi-ethnic study of atherosclerosis Ann. Intern. Med. 2008 148 7 501 508 10.7326/0003-4819-148-7-200804010-00006 18378946 PMC3044648 · DOI
  30. [32]Luc G Bard J-M Lesueur C Plasma cystatin-C and development of coronary heart disease: The PRIME Study Atherosclerosis 2006 185 2 375 380 10.1016/j.atherosclerosis.2005.06.017 16046222 · DOI
  31. [33]Astor BC Shafi T Hoogeveen RC Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population Am. J. Kidney Dis. 2012 59 5 653 662 10.1053/j.ajkd.2011.11.042 22305758 PMC3880682 · DOI
  32. [34]Deo R Fyr CLW Fried LF Kidney dysfunction and fatal cardiovascular disease—An association independent of atherosclerotic events: Results from the Health, Aging, and Body Composition (Health ABC) study Am. Heart J. 2008 155 1 62 68 10.1016/j.ahj.2007.08.012 18082491 · DOI
  33. [35]Liu L Zhu M Meng Q Association between kidney function and the risk of cancer: Results from the China Health and Retirement longitudinal study (CHARLS) J. Cancer 2020 11 21 6429 10.7150/jca.47175 33033526 PMC7532505 · DOI
  34. [36]Mok Y Ballew SH Sang Y Albuminuria, kidney function, and cancer risk in the community Am. J. Epidemiol. 2020 189 9 942 950 10.1093/aje/kwaa043 32219380 PMC7443761 · DOI
  35. [37]Mok Y Matsushita K Sang Y Association of kidney disease measures with cause-specific mortality: the Korean heart study PLoS ONE 2016 11 4 e0153429 10.1371/journal.pone.0153429 27092943 PMC4836674 · DOI
  36. [38]Tu H Wen CP Tsai SP Cancer risk associated with chronic diseases and disease markers: prospective cohort study BMJ 2018 360 k134 10.1136/bmj.k134 29386192 PMC5791146 · DOI

Cited by

Sorted by citations

Authors
Wu, J., Liang, Y., Chen, R., Xu, L., Ou, Z., Liang, H., & Zhao, L.
Affiliations
  • Guangdong Province Women and Children Hospital (CN)
  • Twelfth Guangzhou City People's Hospital (CN)
Corresponding author
  • Liang, Haiying
  • Zhao, Lina
ORCID
Venue
Scientific Reports
Publisher
Springer Science and Business Media LLC
Published
2022-12-23
Volume
12
Issue
1
Pages
22265-22265
ISSN
2045-2322 (ISSN-L)
DOI
10.1038/s41598-022-24722-4
PMC
PMC9789032
OpenAlex
W4312181033
Cited by
10
References
0
Citations by year
2025: 3 · 2024: 6 · 2023: 1
FWCI
1.80
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
  • Health Sciences › Medicine › Physiology › Nutrition and Health in Aging
Keywords
cystatin C, all-cause mortality, cardiovascular mortality, cancer mortality, cause-specific mortality, middle-aged and older adults, sex differences, modifying factors, renal function markers, Health and Retirement Study
MeSH terms
Aged, Cardiovascular Diseases, Cause of Death, Female, Humans, Male, Middle Aged, Mortality, Neoplasms, Prospective Studies, Risk Factors, Cohort Studies, Proportional Hazards Models, Cystatin C

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review